JPWO2022099159A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022099159A5 JPWO2022099159A5 JP2023527250A JP2023527250A JPWO2022099159A5 JP WO2022099159 A5 JPWO2022099159 A5 JP WO2022099159A5 JP 2023527250 A JP2023527250 A JP 2023527250A JP 2023527250 A JP2023527250 A JP 2023527250A JP WO2022099159 A5 JPWO2022099159 A5 JP WO2022099159A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- nucleic acid
- target nucleic
- composition
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 107
- 108020004707 nucleic acids Proteins 0.000 claims 48
- 102000039446 nucleic acids Human genes 0.000 claims 48
- 150000007523 nucleic acids Chemical class 0.000 claims 48
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 42
- 239000000203 mixture Substances 0.000 claims 41
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 31
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 21
- 229960005305 adenosine Drugs 0.000 claims 21
- 230000004048 modification Effects 0.000 claims 20
- 238000012986 modification Methods 0.000 claims 20
- 238000000034 method Methods 0.000 claims 14
- 230000000295 complement effect Effects 0.000 claims 13
- 235000000346 sugar Nutrition 0.000 claims 12
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 11
- 102000055025 Adenosine deaminases Human genes 0.000 claims 11
- 150000008163 sugars Chemical class 0.000 claims 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 239000002777 nucleoside Substances 0.000 claims 4
- 150000008300 phosphoramidites Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000001788 irregular Effects 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 101150075175 Asgr1 gene Proteins 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063111079P | 2020-11-08 | 2020-11-08 | |
| US63/111,079 | 2020-11-08 | ||
| US202163175036P | 2021-04-14 | 2021-04-14 | |
| US63/175,036 | 2021-04-14 | ||
| US202163188415P | 2021-05-13 | 2021-05-13 | |
| US63/188,415 | 2021-05-13 | ||
| US202163196178P | 2021-06-02 | 2021-06-02 | |
| US63/196,178 | 2021-06-02 | ||
| US202163248520P | 2021-09-26 | 2021-09-26 | |
| US63/248,520 | 2021-09-26 | ||
| PCT/US2021/058495 WO2022099159A1 (en) | 2020-11-08 | 2021-11-08 | Oligonucleotide compositions and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548584A JP2023548584A (ja) | 2023-11-17 |
| JPWO2022099159A5 true JPWO2022099159A5 (enExample) | 2024-11-20 |
Family
ID=81456778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023527250A Pending JP2023548584A (ja) | 2020-11-08 | 2021-11-08 | オリゴヌクレオチド組成物及びその方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4240849A1 (enExample) |
| JP (1) | JP2023548584A (enExample) |
| KR (1) | KR20230118716A (enExample) |
| AU (1) | AU2021373062A1 (enExample) |
| CA (1) | CA3197311A1 (enExample) |
| IL (1) | IL302558A (enExample) |
| MX (1) | MX2023005326A (enExample) |
| WO (1) | WO2022099159A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| CN108025089A (zh) | 2015-07-22 | 2018-05-11 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| WO2017210647A1 (en) | 2016-06-03 | 2017-12-07 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| CN109477103A (zh) | 2016-06-22 | 2019-03-15 | ProQR治疗上市公司Ⅱ | 单链rna-编辑寡核苷酸 |
| EP3507366B1 (en) | 2016-09-01 | 2020-10-07 | ProQR Therapeutics II B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| JP7296882B2 (ja) | 2016-11-23 | 2023-06-23 | ウェイブ ライフ サイエンシズ リミテッド | ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 |
| US11597927B2 (en) | 2017-06-02 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2018237194A1 (en) | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| CA3072076A1 (en) | 2017-08-08 | 2019-02-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| SG11202000276YA (en) | 2017-09-18 | 2020-04-29 | Wave Life Sciences Ltd | Technologies for oligonucleotide preparation |
| BR112020020670A2 (pt) | 2018-04-12 | 2021-03-02 | Wave Life Sciences Ltd. | composição de oligonucleotídeo, composição farmacêutica, método para alterar o splicing de uma transcrição alvo, método para tratar distrofia muscular, método para preparar um oligonucleotídeo ou uma composição de oligonucleotídeo do mesmo e oligonucleotídeo |
| TWI844541B (zh) | 2018-05-11 | 2024-06-11 | 新加坡商波濤生命科學有限公司 | 寡核苷酸組成物及其使用方法 |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| WO2022046667A1 (en) * | 2020-08-24 | 2022-03-03 | Wave Life Sciences Ltd. | Cells and non-human animals engineered to express adar1 and uses thereof |
| US20250034564A1 (en) * | 2021-06-29 | 2025-01-30 | Korro Bio, Inc. | Methods and Compositions for ADAR-Mediated Editing |
| KR20240063964A (ko) * | 2021-09-26 | 2024-05-10 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 조성물 및 이의 방법 |
| WO2023049477A2 (en) * | 2021-09-26 | 2023-03-30 | Wave Life Sciences Ltd. | Compositions for editing mecp2 transcripts and methods thereof |
| WO2023069603A1 (en) * | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
| US20250154504A1 (en) | 2022-02-14 | 2025-05-15 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| EP4555086A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| US20260027237A1 (en) | 2022-07-15 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| JP2025525564A (ja) * | 2022-07-18 | 2025-08-05 | エフ. ホフマン-ラ ロシュ アーゲー | オリゴヌクレオチドの編集 |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| JP2025536808A (ja) | 2022-11-24 | 2025-11-07 | プロキューアール・セラピューティクス・セカンド・ベスローテン・フェンノートシャップ | 遺伝性hfeヘモクロマトーシスの治療のためのアンチセンスオリゴヌクレオチド |
| WO2024114908A1 (en) | 2022-11-30 | 2024-06-06 | Eberhard Karls Universität Tübingen | Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| JP2025540146A (ja) | 2022-12-09 | 2025-12-11 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | 心血管疾患の治療のためのアンチセンスオリゴヌクレオチド |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| EP4669753A1 (en) | 2023-02-20 | 2025-12-31 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| EP4669749A1 (en) | 2023-02-21 | 2025-12-31 | Vib Vzw | OLIGONUCLEOTIDES TO MODULATE SYNAPTOGYRIN-3 EXPRESSION |
| WO2024175586A2 (en) | 2023-02-21 | 2024-08-29 | Vib Vzw | Inhibitors of synaptogyrin-3 expression |
| WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| CN121002181A (zh) | 2023-03-27 | 2025-11-21 | ProQR治疗上市公司Ⅱ | 用于治疗肝脏疾病的反义寡核苷酸 |
| WO2024220934A1 (en) | 2023-04-21 | 2024-10-24 | University Of Rochester | Nucleic acid molecules for pseudouridylation |
| CN116444593B (zh) * | 2023-04-28 | 2023-12-26 | 南通大学 | 一种7-脱氮鸟苷亚磷酰胺单体的合成方法 |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Proqr治療上市公司Ii | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2025015338A1 (en) * | 2023-07-13 | 2025-01-16 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2025036984A1 (en) | 2023-08-15 | 2025-02-20 | Airna Corporation | Chemically modified antisense oligonucleotides (asos) and compositions for rna editing |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025072881A2 (en) * | 2023-09-28 | 2025-04-03 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2025072862A1 (en) * | 2023-09-28 | 2025-04-03 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2025073902A1 (en) | 2023-10-06 | 2025-04-10 | Eberhard Karls Universität Tübingen | Chemical and sequence optimisation of antisense oligonucleotides for adar-mediated rna editing |
| WO2025083268A1 (en) | 2023-10-20 | 2025-04-24 | Airna Corporation | Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025128799A1 (en) * | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| WO2025160090A1 (en) * | 2024-01-22 | 2025-07-31 | Wave Life Sciences Ltd. | Technol. ogies useful for oligonucleotide preparation |
| WO2025172372A1 (en) | 2024-02-12 | 2025-08-21 | Airna Corporation | Conjugate for targeted delivery of an antisense oligonucleotide |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| GB202405143D0 (en) | 2024-04-11 | 2024-05-29 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of poly-q disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9975916B2 (en) * | 2012-11-06 | 2018-05-22 | President And Fellows Of Harvard College | Compositions and methods relating to complex nucleic acid nanostructures |
| EP3507366B1 (en) * | 2016-09-01 | 2020-10-07 | ProQR Therapeutics II B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| JP7364472B2 (ja) * | 2017-05-18 | 2023-10-18 | ザ・ブロード・インスティテュート・インコーポレイテッド | 標的化された核酸編集のための系、方法、及び組成物 |
| WO2018237194A1 (en) * | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| BR112022006205A2 (pt) * | 2019-10-06 | 2022-07-19 | Wave Life Sciences Ltd | Oligonucleotídeo; composição farmacêutica; composição de oligonucleotídeo; fosforamidita; método de preparação de um oligonucleotídeo ou composição; método para caracterizar um oligonucleotídeo ou uma composição; método para modificar uma adenosina alvo em um ácido nucleico alvo; método para desaminar uma adenosina alvo em um ácido nucleico alvo; método para prevenção ou tratamento de uma afecção, distúrbio ou doença passível de uma mutação de g para a; e composto, oligonucleotídeo, composição ou método |
-
2021
- 2021-11-08 CA CA3197311A patent/CA3197311A1/en active Pending
- 2021-11-08 EP EP21890258.3A patent/EP4240849A1/en active Pending
- 2021-11-08 KR KR1020237019215A patent/KR20230118716A/ko active Pending
- 2021-11-08 IL IL302558A patent/IL302558A/en unknown
- 2021-11-08 JP JP2023527250A patent/JP2023548584A/ja active Pending
- 2021-11-08 MX MX2023005326A patent/MX2023005326A/es unknown
- 2021-11-08 WO PCT/US2021/058495 patent/WO2022099159A1/en not_active Ceased
- 2021-11-08 AU AU2021373062A patent/AU2021373062A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022099159A5 (enExample) | ||
| JP2025165976A5 (enExample) | ||
| JPWO2021071858A5 (enExample) | ||
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| JPWO2020227691A5 (enExample) | ||
| JPWO2021071788A5 (enExample) | ||
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP2018528781A5 (enExample) | ||
| JPH09511250A (ja) | 核酸治療に有用な修飾オリゴヌクレオチド及び中間体 | |
| JPWO2019217784A5 (enExample) | ||
| JPWO2020118246A5 (enExample) | ||
| WO2001085751A1 (en) | Polymeric compounds useful as prodrugs | |
| JP2019534009A5 (enExample) | ||
| JP7724259B2 (ja) | 新規のチオホスホラミダイト | |
| JP2021515784A (ja) | 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法 | |
| KR20200104347A (ko) | 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드 | |
| US20160122372A1 (en) | Tricyclic nucleosides and oligomeric compounds prepared therefrom | |
| JP2000512630A (ja) | 2’―置換ヌクレオシドおよびオリゴヌクレオチド誘導体 | |
| JPWO2023049477A5 (enExample) | ||
| JPWO2019217708A5 (enExample) | ||
| JPWO2023049475A5 (enExample) | ||
| JP2018518167A5 (enExample) | ||
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| JPWO2019140452A5 (enExample) | ||
| JPH1135595A (ja) | アンチセンスオリゴヌクレオチド及びそれを用いた制癌剤 |